International Journal of Clinical Oncology

, Volume 6, Issue 6, pp 296–301

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

  • H. Kunikane
  • K. Watanabe
  • M. Fukuoka
  • N. Saijo
  • K. Furuse
  • H. Ikegami
  • Y. Ariyoshi
  • S. Kishimoto
ORIGINAL ARTICLE

DOI: 10.1007/s10147-001-8031-y

Cite this article as:
Kunikane, H., Watanabe, K., Fukuoka, M. et al. Int J Clin Oncol (2001) 6: 296. doi:10.1007/s10147-001-8031-y

Abstract

Background. We studied the clinical effect of recombinant human erythropoietin (r-huEPO) on anemia induced by two courses of cisplatin-based chemotherapy in patients with non-small cell lung cancer (NSCLC).

Methods. Seventy-two patients with NSCLC were randomized into three groups, receiving 100, or 200 IU/kg of r-huEPO, or placebo. The r-huEPO and placebo were administered subcutaneously three times a week for 6 weeks, starting 2 weeks after the initiation of chemotherapy.

Results. In the 53 evaluable patients, hemoglobin (Hb) levels at the nadir after the second cycle of chemotherapy were significantly elevated compared with the nadir after the first cycle in both r-huEPO treated groups, while this level was decreased in the placebo group. Hb levels at the end of the second course of chemotherapy (week 8) in both r-huEPO groups were higher than that in the placebo groups. No adverse drug reaction attributable to r-huEPO was observed. Serum erythropoietin levels after the administration of r-huEPO were higher than those after placebo administration.

Conclusions. r-huEPO had an effect in preventing anemia in patients with NSCLC who had cisplatin-based chemotherapy.

Key words Non-small cell lung cancerChemotherapyAnemiaErythropoietinRandomized control trial

Copyright information

© The Japan Society of Clinical Oncology 2001

Authors and Affiliations

  • H. Kunikane
    • 1
  • K. Watanabe
    • 1
  • M. Fukuoka
    • 2
  • N. Saijo
    • 3
  • K. Furuse
    • 4
  • H. Ikegami
    • 5
  • Y. Ariyoshi
    • 6
  • S. Kishimoto
    • 7
  1. 1.Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama 240-8555, Japan Tel. +81-45-331-1961; Fax +81-45-331-1960 e-mail: kunikane@courante.plala.or.jpJP
  2. 2.Fourth Department of Internal Medicine, Kinki University School of Medicine, Osaka-sayama, JapanJP
  3. 3.Department of Medical Oncology and Radiation Oncology, National Cancer Center Central Hospital, Tokyo, JapanJP
  4. 4.Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Sakai, JapanJP
  5. 5.Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, JapanJP
  6. 6.Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, JapanJP
  7. 7.Osaka Prefectural Habikino Hospital, Habikino, JapanJP